First Time Loading...

Avalo Therapeutics Inc
NASDAQ:AVTX

Watchlist Manager
Avalo Therapeutics Inc Logo
Avalo Therapeutics Inc
NASDAQ:AVTX
Watchlist
Price: 14.2 USD 9.23% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

AVTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Avalo Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one AVTX stock under the Base Case scenario is 38.81 USD. Compared to the current market price of 14.2 USD, Avalo Therapeutics Inc is Undervalued by 63%.

Key Points:
AVTX Intrinsic Value
Base Case
38.81 USD
Undervaluation 63%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Avalo Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AVTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Avalo Therapeutics Inc

Provide an overview of the primary business activities
of Avalo Therapeutics Inc.

What unique competitive advantages
does Avalo Therapeutics Inc hold over its rivals?

What risks and challenges
does Avalo Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Avalo Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Avalo Therapeutics Inc.

Provide P/S
for Avalo Therapeutics Inc.

Provide P/E
for Avalo Therapeutics Inc.

Provide P/OCF
for Avalo Therapeutics Inc.

Provide P/FCFE
for Avalo Therapeutics Inc.

Provide P/B
for Avalo Therapeutics Inc.

Provide EV/S
for Avalo Therapeutics Inc.

Provide EV/GP
for Avalo Therapeutics Inc.

Provide EV/EBITDA
for Avalo Therapeutics Inc.

Provide EV/EBIT
for Avalo Therapeutics Inc.

Provide EV/OCF
for Avalo Therapeutics Inc.

Provide EV/FCFF
for Avalo Therapeutics Inc.

Provide EV/IC
for Avalo Therapeutics Inc.

Show me price targets
for Avalo Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Avalo Therapeutics Inc?

How accurate were the past Revenue estimates
for Avalo Therapeutics Inc?

What are the Net Income projections
for Avalo Therapeutics Inc?

How accurate were the past Net Income estimates
for Avalo Therapeutics Inc?

What are the EPS projections
for Avalo Therapeutics Inc?

How accurate were the past EPS estimates
for Avalo Therapeutics Inc?

What are the EBIT projections
for Avalo Therapeutics Inc?

How accurate were the past EBIT estimates
for Avalo Therapeutics Inc?

Compare the revenue forecasts
for Avalo Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Avalo Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Avalo Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Avalo Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Avalo Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Avalo Therapeutics Inc with its peers.

Analyze the financial leverage
of Avalo Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Avalo Therapeutics Inc.

Provide ROE
for Avalo Therapeutics Inc.

Provide ROA
for Avalo Therapeutics Inc.

Provide ROIC
for Avalo Therapeutics Inc.

Provide ROCE
for Avalo Therapeutics Inc.

Provide Gross Margin
for Avalo Therapeutics Inc.

Provide Operating Margin
for Avalo Therapeutics Inc.

Provide Net Margin
for Avalo Therapeutics Inc.

Provide FCF Margin
for Avalo Therapeutics Inc.

Show all solvency ratios
for Avalo Therapeutics Inc.

Provide D/E Ratio
for Avalo Therapeutics Inc.

Provide D/A Ratio
for Avalo Therapeutics Inc.

Provide Interest Coverage Ratio
for Avalo Therapeutics Inc.

Provide Altman Z-Score Ratio
for Avalo Therapeutics Inc.

Provide Quick Ratio
for Avalo Therapeutics Inc.

Provide Current Ratio
for Avalo Therapeutics Inc.

Provide Cash Ratio
for Avalo Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Avalo Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Avalo Therapeutics Inc?

What is the current Free Cash Flow
of Avalo Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Avalo Therapeutics Inc.

Financials

Balance Sheet Decomposition
Avalo Therapeutics Inc

Current Assets 8.4m
Cash & Short-Term Investments 7.4m
Receivables 136k
Other Current Assets 844k
Non-Current Assets 12.6m
PP&E 2m
Intangibles 10.5m
Other Non-Current Assets 131k
Current Liabilities 4.6m
Accounts Payable 446k
Accrued Liabilities 4.2m
Non-Current Liabilities 9.1m
Other Non-Current Liabilities 9.1m
Efficiency

Earnings Waterfall
Avalo Therapeutics Inc

Revenue
1.9m USD
Cost of Revenue
-1.3m USD
Gross Profit
640k USD
Operating Expenses
-24.1m USD
Operating Income
-23.4m USD
Other Expenses
-8.1m USD
Net Income
-31.5m USD

Free Cash Flow Analysis
Avalo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

AVTX Profitability Score
Profitability Due Diligence

Avalo Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

24/100
Profitability
Score

Avalo Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

AVTX Solvency Score
Solvency Due Diligence

Avalo Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
39/100
Solvency
Score

Avalo Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AVTX Price Targets Summary
Avalo Therapeutics Inc

Wall Street analysts forecast AVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AVTX is 35.7 USD with a low forecast of 35.35 USD and a high forecast of 36.75 USD.

Lowest
Price Target
35.35 USD
149% Upside
Average
Price Target
35.7 USD
151% Upside
Highest
Price Target
36.75 USD
159% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AVTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AVTX Price
Avalo Therapeutics Inc

1M 1M
+193%
6M 6M
-44%
1Y 1Y
-98%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
14.2
52w Low
4.02
52w High
1 060.8
Price Metrics
Average Annual Return -41.52%
Standard Deviation of Annual Returns 28.13%
Max Drawdown -100%
Shares Statistics
Market Capitalization 11.4m USD
Shares Outstanding 801 611
Percentage of Shares Shorted 7.59%

AVTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Avalo Therapeutics Inc Logo
Avalo Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

11.4m USD

Dividend Yield

0%

Description

Avalo Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 42 full-time employees. The company went IPO on 2015-11-13. The firm discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.

Contact

MARYLAND
Rockville
540 Gaither Rd Ste 400
+14105228707.0
https://www.avalotx.com/

IPO

2015-11-13

Employees

42

Officers

Chairman of the Board, President & CEO
Dr. Garry A. Neil M.D.
CFO & Head of Investor relations
Mr. Christopher Ryan Sullivan
Founder and Chairman of Scientific Advisory Board
Dr. Solomon H. Snyder M.D.
Founder and Member of Scientific Advisory Board
Dr. Barbara S. Slusher Ph.D.
Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations
Dr. Lisa Hegg Ph.D.
Senior Vice President of Global Regulatory Affairs & Quality Assurance
Ms. Colleen Matkowski
Show More
Senior Vice President of CMC & Technical Operations
Dr. Dino C. Miano Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AVTX stock?

The intrinsic value of one AVTX stock under the Base Case scenario is 38.81 USD.

Is AVTX stock undervalued or overvalued?

Compared to the current market price of 14.2 USD, Avalo Therapeutics Inc is Undervalued by 63%.